At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 2, 2026 at 06:00 ET
Zymeworks reported strong 2025 financial results with 39% revenue growth to $106.0 million and a 34% reduction in net loss to $81.1 million. The company secured $250.0 million in non-dilutive financing from Royalty Pharma and is executing a $125.0 million share repurchase program, having already used $62.5 million. Key catalysts include the potential U.S. approval and 2026 launch of Ziihera in first-line HER2+ gastroesophageal cancer, which could trigger up to $440.0 million in milestone payments.
- Total revenue for 2025 was $106.0 million, up 39% from $76.3 million in 2024
- Net loss for 2025 was $81.1 million, a 34% improvement from $122.7 million in 2024
- Entered into $250.0 million non-recourse royalty-backed note financing with Royalty Pharma
- Utilized $62.5 million of a $125.0 million share repurchase program as of March 2, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access